Nature Communications (Oct 2022)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

  • Cameron S. Fraser,
  • Johan K. E. Spetz,
  • Xingping Qin,
  • Adam Presser,
  • Jonathan Choiniere,
  • Chendi Li,
  • Stacey Yu,
  • Frances Blevins,
  • Aaron N. Hata,
  • Jeffrey W. Miller,
  • Gary A. Bradshaw,
  • Marian Kalocsay,
  • Vaishali Sanchorawala,
  • Shayna Sarosiek,
  • Kristopher A. Sarosiek

DOI
https://doi.org/10.1038/s41467-022-33461-z
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 19

Abstract

Read online

Immunoglobulin light chain amyloidosis is a lethal hematologic disorder driven by clonal plasma cells producing abnormal light chains that damage healthy tissues. Fraser et al. show that BH3 mimetics, which inhibit pro-survival proteins BCL-2 or MCL-1, can effectively eliminate diseased cells.